CureVac NV (5CV) - Net Assets

Latest as of September 2025: €871.23 Million EUR ≈ $1.02 Billion USD

Based on the latest financial reports, CureVac NV (5CV) has net assets worth €871.23 Million EUR (≈ $1.02 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.14 Billion ≈ $1.33 Billion USD) and total liabilities (€267.39 Million ≈ $312.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 5CV financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€871.23 Million
% of Total Assets	76.52%
Annual Growth Rate	67.01%
5-Year Change	-2.07%
10-Year Change	N/A
Growth Volatility	95.78

CureVac NV - Net Assets Trend (2018–2024)

This chart illustrates how CureVac NV's net assets have evolved over time, based on quarterly financial data. Also explore CureVac NV balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for CureVac NV (2018–2024)

The table below shows the annual net assets of CureVac NV from 2018 to 2024. For live valuation and market cap data, see 5CV market cap overview.

Year	Net Assets	Change
2024-12-31	€696.61 Million ≈ $814.41 Million	+34.76%
2023-12-31	€516.94 Million ≈ $604.36 Million	-3.06%
2022-12-31	€533.25 Million ≈ $623.43 Million	-22.55%
2021-12-31	€688.48 Million ≈ $804.90 Million	-3.22%
2020-12-31	€711.35 Million ≈ $831.64 Million	+1761.95%
2019-12-31	€-42.80 Million ≈ $-50.04 Million	-233.41%
2018-12-31	€32.08 Million ≈ $37.51 Million	--

Equity Component Analysis

This analysis shows how different components contribute to CureVac NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 98772200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€2.10 Billion	301.52%
Total Equity	€696.61 Million	100.00%

CureVac NV Competitors by Market Cap

The table below lists competitors of CureVac NV ranked by their market capitalization.

Company	Market Cap
O-Bank Co Ltd TW:2897	$885.38 Million
Sichuan Jinshi Technology Co Ltd Class A SHE:002951	$885.41 Million
Data 3 Ltd AU:DTL	$886.60 Million
Barco NV BR:BAR	$886.82 Million
TeamViewer AG F:TMV	$885.29 Million
CHA Biotech Co. Ltd KQ:085660	$885.14 Million
V V Food & Beverage Co Ltd SHG:600300	$885.03 Million
CW Enerji SA IS:CWENE	$884.89 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CureVac NV's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 516,941,000 to 696,608,000, a change of 179,667,000 (34.8%).
Net income of 162,186,000 contributed positively to equity growth.
Other factors increased equity by 17,481,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€162.19 Million	+23.28%
Other Changes	€17.48 Million	+2.51%
Total Change	€-	34.76%

Book Value vs Market Value Analysis

This analysis compares CureVac NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.26x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 21.48x to 1.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2018-12-31	€0.18	€3.91	x
2019-12-31	€-0.24	€3.91	x
2020-12-31	€3.94	€3.91	x
2021-12-31	€3.68	€3.91	x
2022-12-31	€2.74	€3.91	x
2023-12-31	€2.31	€3.91	x
2024-12-31	€3.11	€3.91	x

Capital Efficiency Dashboard

This dashboard shows how efficiently CureVac NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 23.28%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 30.30%
• Asset Turnover: 0.67x
• Equity Multiplier: 1.15x
Recent ROE (23.28%) is above the historical average (-53.41%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2018	-222.05%	-553.50%	0.10x	3.92x	€-74.45 Million
2019	0.00%	-573.46%	0.13x	0.00x	€-95.59 Million
2020	-18.25%	-265.44%	0.03x	2.12x	€-200.93 Million
2021	-59.80%	-399.76%	0.09x	1.68x	€-480.56 Million
2022	-46.70%	-369.37%	0.08x	1.61x	€-302.35 Million
2023	-50.33%	-483.96%	0.07x	1.52x	€-311.86 Million
2024	23.28%	30.30%	0.67x	1.15x	€92.53 Million

Industry Comparison

This section compares CureVac NV's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $698,488,333
Average return on equity (ROE) among peers: -63.13%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
CureVac NV (5CV)	€871.23 Million	-222.05%	0.31x	$885.32 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$5.54 Million	-319.56%	1.20x	$157.03 Million
Theravance Biopharma Inc (0TB)	$441.80 Million	197.40%	0.37x	$828.57 Million
PreveCeutical Medical Inc (18H)	$-4.10 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$538.39 Million	-12.38%	0.07x	$44.01 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$32.50 Million	-376.16%	5.37x	$1.12 Billion
ZAI LAB LTD0000006 (1ZLB)	$1.38 Billion	-51.05%	0.17x	$2.05 Billion
BioNTech SE (22UA)	$493.49 Million	-36.28%	0.62x	$23.24 Billion
Ascletis Pharma Inc (2VJ)	$2.54 Billion	-12.40%	0.05x	$2.05 Billion
ALPHAMAB ONCOLO.DL-000002 (3NK)	$1.56 Billion	-20.91%	0.36x	$978.26 Million
BIOMIND LABS INC. (3XI)	$-247.66K	0.00%	0.00x	$3.31 Million

About CureVac NV

F:5CV Germany Biotechnology

Market Cap

$1.03 Billion

€879.52 Million EUR

Market Cap Rank

#9657 Global

#1171 in Germany

Share Price

€3.91

Change (1 day)

-0.61%

52-Week Range

€3.02 - €4.86

All Time High

€108.20